MAP2K7 and melanoma: Of note, YUMM1.7 melanoma are by far less immunogenic when compared to RIG-I-sensitive YUMMER 1.7 melanoma,27 and we provide evidence that combined BRAF/MEK inhibition renders even YUMM1.7 melanoma susceptible to RIG-I agonist-based immunotherapy.